GeneNews Limited, a company focused on developing simple blood-based biomarker tests for the early detection of diseases and personalized health management, today announced it has signed an agreement with an Asian Biomedical consortium to develop blood-based biomarkers for the detection and management of prostate diseases.
Under the agreement, the consortium will provide US$2 million to GeneNews to conduct the work required to identify and validate biomarkers related to prostate disease using its proprietary Sentinel Principle and Discovery Funnel technologies. If a biomarker panel is successfully validated, GeneNews will then develop and commercialize a prostate disease test based on these biomarkers to be known as ProstateSentry. All intellectual property generated in the identification and validation of prostate disease biomarkers shall remain vested in GeneNews and the consortium shall be entitled to receive certain royalties from the commercial sales of ProstateSentry.